Millipore Sigma Vibrant Logo

GF25 Anti-VEGF (Ab-3) Mouse mAb (14-124)

This Anti-VEGF (Ab-3) Mouse mAb (14-124) is validated for use in Immunoblotting, Paraffin Sections for the detection of VEGF (Ab-3).

Anti-VEGF (Ab-3) Mouse mAb (14-124): SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.

Synonyme: Anti-Vascular Permeability Factor, Anti-VPF, Anti-Vascular Endothelial Growth Factor

GF25
  
Preis wird abgerufen...
Preis nicht abrufbar
Die Mindestmenge muss ein Vielfaches sein von
Maximum Quantity is
Bei Bestätigung Weitere Informationen
Sie haben () gespart
 
—
Bitte erfragen
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

       

      Kontakt zum Kundenservice

      Übersicht

      Replacement Information

      Key Spec Table

      Species ReactivityHostAntibody Type
      HMMonoclonal Antibody
      Description
      Overview

      This product has been discontinued.



      Recognizes the ~31-50 kDa VEGF121, VEGF165, VEGF189, and VEGF206 proteins.
      Catalogue NumberGF25
      Brand Family Calbiochem®
      SynonymsAnti-Vascular Permeability Factor, Anti-VPF, Anti-Vascular Endothelial Growth Factor
      References
      ReferencesKlagsbrun, M. and Soker, S., 1993. Current Biology 3 699.
      Senger, D., et al. 1993. Cancer and Metastasis Reviews In Press.
      Brown, L., et al. 1992. Kidney International 42, 1457.
      Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275.
      Product Information
      FormLiquid
      FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
      Negative controlNormal brain
      Positive controlRecombinant VEGF protein or fetal kidney
      Preservative≤0.1% sodium azide
      Applications
      Application ReferencesImmunoblotting Uthoff, S.M.S., et al. 2002. Int. J. Cancer 101, 32. Sauter, E.R., et al. 1999. Clin. Cancer Res. 5, 775.
      Key Applications Immunoblotting (Western Blotting)
      Paraffin Sections
      Application NotesImmunoblotting (0.5 µg/ml, see comments and application references)
      Paraffin Sections (5.0 µg/ml, trypsin or pressure cooker pre-treatment required)
      Application CommentsFor immunoblotting, include 1% BSA with the primary antibody. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogena synthetic peptide corresponding to amino acids from the N-terminus of human VEGF₁₆₅
      ImmunogenHuman
      Clone14-124
      HostMouse
      IsotypeIgG₁
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Yes
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      GF25 0

      Documentation

      Anti-VEGF (Ab-3) Mouse mAb (14-124) Analysenzertifikate

      TitelChargennummer
      GF25

      Literatur

      Übersicht
      Klagsbrun, M. and Soker, S., 1993. Current Biology 3 699.
      Senger, D., et al. 1993. Cancer and Metastasis Reviews In Press.
      Brown, L., et al. 1992. Kidney International 42, 1457.
      Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275.

      Literaturstellen

      Titel
    • Sonja M.S. Uthoff, et al. (2002) VEGF Isoforms and Mutations in Human Colorectal Cancer. International Journal of Cancer 101, 32-36.
    • Edward R. Sauter, et al. (1999) Vascular Endothelial Growth Factor Is a Marker of Tumor Invasion and Metastasis in Squamous Cell Carcinomas of the Head and Neck. Clinical Cancer Research 5, 775-782.
      		•
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision23-August-2007 RFH
      SynonymsAnti-Vascular Permeability Factor, Anti-VPF, Anti-Vascular Endothelial Growth Factor
      ApplicationImmunoblotting (0.5 µg/ml, see comments and application references)
      Paraffin Sections (5.0 µg/ml, trypsin or pressure cooker pre-treatment required)
      DescriptionPurified mouse monoclonal antibody generated by immunizing Balb/c mice with the specified immunogen and fusing splenocytes with mouse SP2/0 cells. Recognizes the ~31-50 kDa VEGF121, VEGF165, VEGF189, and VEGF206 proteins.
      BackgroundVascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a secreted heparin binding cytokine expressed in tumor and animal cells. VEGF has been implicated in the control of angiogenesis due to its selective mitogenic stimulation of vascular endothelial cells and enhancement of vascular permeability. Other effects of VEGF on vascular endothelial cells include; increasing intracellular calcium, stimulating inositol triphosphate formation, induction of von Willebrand factor release, and stimulating tissue factor expression. VEGF is a ~46 kDa dimer of two identical disulfide-linked subunits existing in four molecular species; 121, 165, 189, and 206 amino acid residues long.
      HostMouse
      Immunogen speciesHuman
      Immunogena synthetic peptide corresponding to amino acids from the N-terminus of human VEGF₁₆₅
      Clone14-124
      IsotypeIgG₁
      Specieshuman
      Positive controlRecombinant VEGF protein or fetal kidney
      Negative controlNormal brain
      FormLiquid
      FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsFor immunoblotting, include 1% BSA with the primary antibody. Antibody should be titrated for optimal results in individual systems.
      Storage +2°C to +8°C
      Do Not Freeze Yes
      Toxicity Standard Handling
      ReferencesKlagsbrun, M. and Soker, S., 1993. Current Biology 3 699.
      Senger, D., et al. 1993. Cancer and Metastasis Reviews In Press.
      Brown, L., et al. 1992. Kidney International 42, 1457.
      Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275.
      Citation
    • Sonja M.S. Uthoff, et al. (2002) VEGF Isoforms and Mutations in Human Colorectal Cancer. International Journal of Cancer 101, 32-36.
    • Edward R. Sauter, et al. (1999) Vascular Endothelial Growth Factor Is a Marker of Tumor Invasion and Metastasis in Squamous Cell Carcinomas of the Head and Neck. Clinical Cancer Research 5, 775-782.
      		•
      Application referencesImmunoblotting Uthoff, S.M.S., et al. 2002. Int. J. Cancer 101, 32. Sauter, E.R., et al. 1999. Clin. Cancer Res. 5, 775.

      Verwandte Produkte & Anwendungen

      Related Products

      Bestellnummer Beschreibung  
      PC37 Anti-VEGF (Ab-2) Rabbit pAb Preis & Verfügbarkeit

      Kategorien

      Life Science Research > Antibodies and Assays > Primary Antibodies